IGM Biosciences, developing IgM antibodies for various diseases, sees Q1 2023 cash decrease, but collaboration revenues rise. Imvotamab trial results disappoint; focus shifts to combination therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback